Figure 2From: pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 Correlation of efficacy endpoints with the p53 IHC expression level. A) Progression-free survival (PFS, n = 50; p[global] = 0.03). B) Overall survival (OS, n = 50; p[global] = 0.91).Back to article page